226 related articles for article (PubMed ID: 18630512)
1. Flow cytometric phenotype of rhabdomyosarcoma bone marrow metastatic cells and its implication in differential diagnosis with neuroblastoma.
Bozzi F; Collini P; Aiello A; Barzanò E; Gambirasio F; Podda M; Meazza C; Ferrari A; Luksch R
Anticancer Res; 2008; 28(3A):1565-9. PubMed ID: 18630512
[TBL] [Abstract][Full Text] [Related]
2. Flow cytometric analysis of peripheral blood and bone marrow for tumor cells in patients with neuroblastoma.
Komada Y; Zhang XL; Zhou YW; Inaba H; Deguchi T; Azuma E; Sakurai M
Cancer; 1998 Feb; 82(3):591-9. PubMed ID: 9452279
[TBL] [Abstract][Full Text] [Related]
3. Detection of micrometastasis of neuroblastoma to bone marrow and tumor dissemination to hematopoietic autografts using flow cytometry and reverse transcriptase-polymerase chain reaction.
Tsang KS; Li CK; Tsoi WC; Leung Y; Shing MM; Chik KW; Lee V; Ng MH; Yuen P
Cancer; 2003 Jun; 97(11):2887-97. PubMed ID: 12767104
[TBL] [Abstract][Full Text] [Related]
4. Measuring circulating neuroblastoma cells by quantitative reverse transcriptase-polymerase chain reaction analysis.
Cheung IY; Sahota A; Cheung NK
Cancer; 2004 Nov; 101(10):2303-8. PubMed ID: 15484213
[TBL] [Abstract][Full Text] [Related]
5. Detection of residual neuroblastoma cells in bone marrow: comparison of flow cytometry with immunocytochemistry.
Swerts K; De Moerloose B; Dhooge C; Brichard B; Benoit Y; Laureys G; Philippé J
Cytometry B Clin Cytom; 2004 Sep; 61(1):9-19. PubMed ID: 15351977
[TBL] [Abstract][Full Text] [Related]
6. Myogenin--a more specific target for RT-PCR detection of rhabdomyosarcoma than MyoD1.
Michelagnoli MP; Burchill SA; Cullinane C; Selby PJ; Lewis IJ
Med Pediatr Oncol; 2003 Jan; 40(1):1-8. PubMed ID: 12426678
[TBL] [Abstract][Full Text] [Related]
7. Flow cytometry and fluorescence in situ hybridization to detect residual neuroblastoma cells in bone marrow.
Okcu MF; Wang RY; Bueso-Ramos C; Schober W; Weidner D; Andrassy R; Blakely M; Russell H; Ozkan A; Kuttesch J; Andreeff M; Chan KW; Ater J
Pediatr Blood Cancer; 2005 Nov; 45(6):787-95. PubMed ID: 15929127
[TBL] [Abstract][Full Text] [Related]
8. Molecular detection of GAGE expression in peripheral blood and bone marrow: utility as a tumor marker for neuroblastoma.
Cheung IY; Cheung NK
Clin Cancer Res; 1997 May; 3(5):821-6. PubMed ID: 9815755
[TBL] [Abstract][Full Text] [Related]
9. Detecting CD56+/NB84+/CD45- immunophenotype in the bone marrow of patients with metastatic neuroblastoma using flow cytometry.
Bozzi F; Gambirasio F; Luksch R; Collini P; Brando B; Fossati-Bellani F
Anticancer Res; 2006; 26(5A):3281-7. PubMed ID: 17094441
[TBL] [Abstract][Full Text] [Related]
10. Prognostic influence of minimal residual disease detected by flow cytometry and peripheral blood stem cell transplantation by CD34+ selection in childhood advanced neuroblastoma.
Cai JY; Tang YJ; Jiang LM; Pan C; Chen J; Tang JY
Pediatr Blood Cancer; 2007 Dec; 49(7):952-7. PubMed ID: 17514736
[TBL] [Abstract][Full Text] [Related]
11. Detection of neuroblastoma cells during clinical follow up: advanced flow cytometry and rt-PCR for tyrosine hydroxylase using both conventional and real-time PCR.
Esser R; Glienke W; Bochennek K; Erben S; Quaiser A; Pieper C; Eggert A; Schramm A; Astrahantseff K; Hansmann ML; Schwabe D; Klingebiel T; Koehl U
Klin Padiatr; 2011 Nov; 223(6):326-31. PubMed ID: 22095188
[TBL] [Abstract][Full Text] [Related]
12. Minimal residual disease is a prognostic marker for neuroblastoma with bone marrow infiltration.
Cai JY; Pan C; Tang YJ; Chen J; Ye QD; Zhou M; Xue H; Tang JY
Am J Clin Oncol; 2012 Jun; 35(3):275-8. PubMed ID: 21537148
[TBL] [Abstract][Full Text] [Related]
13. Flow cytometric evaluation of bone marrow plasma cells using CD19, CD45, CD56, CD38, and CD138 and correlation with bone marrow infiltration ratio in multiple myeloma patients.
Kara IO; Sahin B; Paydas S; Cetiner S
Saudi Med J; 2004 Nov; 25(11):1587-92. PubMed ID: 15573184
[TBL] [Abstract][Full Text] [Related]
14. Quantitation of GD2 synthase mRNA by real-time reverse transcription-polymerase chain reaction: utility in bone marrow purging of neuroblastoma by anti-GD2 antibody 3F8.
Cheung IY; Lo Piccolo MS; Collins N; Kushner BH; Cheung NK
Cancer; 2002 Jun; 94(11):3042-8. PubMed ID: 12115395
[TBL] [Abstract][Full Text] [Related]
15. Detection of isolated tumor cells in peripheral blood and in BM: evaluation of a new enrichment method.
Naume B; Borgen E; Tøssvik S; Pavlak N; Oates D; Nesland JM
Cytotherapy; 2004; 6(3):244-52. PubMed ID: 15203981
[TBL] [Abstract][Full Text] [Related]
16. Bone marrow of neuroblastoma patients shows downregulation of CXCL12 expression and presence of IFN signature.
Scaruffi P; Morandi F; Gallo F; Stigliani S; Parodi S; Moretti S; Bonassi S; Fardin P; Garaventa A; Zanazzo G; Pistoia V; Tonini GP; Corrias MV
Pediatr Blood Cancer; 2012 Jul; 59(1):44-51. PubMed ID: 21994039
[TBL] [Abstract][Full Text] [Related]
17. Real-time RT-PCR of tyrosine hydroxylase to detect bone marrow involvement in advanced neuroblastoma.
Pession A; Libri V; Sartini R; Conforti R; Magrini E; Bernardi L; Fronza R; Olivotto E; Prete A; Tonelli R; Paolucci G
Oncol Rep; 2003; 10(2):357-62. PubMed ID: 12579272
[TBL] [Abstract][Full Text] [Related]
18. Rhabdomyosarcoma masquerading as acute leukemia.
Shinkoda Y; Nagatoshi Y; Fukano R; Nishiyama K; Okamura J
Pediatr Blood Cancer; 2009 Feb; 52(2):286-7. PubMed ID: 18837429
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic utility of PHOX2B in primary and treated neuroblastoma and in neuroblastoma metastatic to the bone marrow.
Hata JL; Correa H; Krishnan C; Esbenshade AJ; Black JO; Chung DH; Mobley BC
Arch Pathol Lab Med; 2015 Apr; 139(4):543-6. PubMed ID: 25822764
[TBL] [Abstract][Full Text] [Related]
20. Combined automatic immunological and molecular cytogenetic analysis allows exact identification and quantification of tumor cells in the bone marrow.
Méhes G; Luegmayr A; Ambros IM; Ladenstein R; Ambros PF
Clin Cancer Res; 2001 Jul; 7(7):1969-75. PubMed ID: 11448912
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
